True, if the uptake is good it's gangbusters for the stock price. At around $10,000 a month, how does this compare with the price of other existing treatments for MCL?
MCL isn't that important - it's CLL that's key. It may be an expensive ticket if you've unfortunately come down with CLL, but it sure beats the alternative.
I understand about the efficacy. I am curious as to how much more expensive ibrutinib is compared to existing treatments for MCL and CLL for that matter. I am trying to get a handle on whether insurance companies may balk given the price tag.